Iovance Biotherapeutics, Inc. (IOVA) experienced a significant intraday surge of 12.04% on Wednesday, reflecting strong investor interest in the biotechnology company during the regular trading session.

The sharp increase appears to be driven by a series of positive analyst actions. Barclays maintained a Buy rating on the stock and raised its price target from $10 to $11. Additionally, Citizens upgraded Iovance Biotherapeutics from Market Perform to Market Outperform and set a price target of $5. Baird also raised its price target from $3 to $4, though it maintained a Neutral rating on the shares.

These analyst endorsements and target price increases likely boosted investor confidence in the company's prospects, contributing to the substantial stock price appreciation during the trading day.